Bachem Holding AG (BANB.SW) — Quality & forensics
As of 2026-09-18 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.
The Closelook module scores
- Valuation 34
- Quality 41
- Growth 38
- Balance sheet 76
- Cash quality 56
- Capital allocation 47
- Momentum 78
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the BANB.SW chart & overview
FAQ · from the current data · as of 2026-09-18
Quick answers
What is Bachem Holding AG's Closelook quality reading?
The composite reads 50/100 across 7 modules, as of 2026-09-18: valuation 34, quality 41, growth 38, balance sheet 76, cash quality 56, capital allocation 47, momentum 78. Closelook scores are research diary readings, not ratings or investment advice.
What is Bachem Holding AG's Altman Z-Score?
6.72, which sits in the safe zone (above 2.99) as of 2026-09-18. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Bachem Holding AG's Piotroski F-Score?
6 of 8, as of 2026-09-18. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Bachem Holding AG's Beneish M-Score indicate?
-2.83 — below the −1.78 manipulation-risk threshold, as of 2026-09-18. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelook universe
then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- BION.SW BB Biotech AGindustry
- ARGX.BR Argen-Xindustry
- ARGX argenx NV ADRindustry
- ONC BeiGene, Ltd.industry
- REGN Regeneron Pharmaceuticals Incindustry
- UCB.BR UCB SAindustry
- MRNA Moderna Incindustry
- TWST Twist Bioscience Corpindustry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- SMMT Summit Therapeutics PLCindustry
- RXRX Recursion Pharmaceuticals Incindustry
- HALO Halozyme Therapeutics Incindustry
- GMAB Genmab ASindustry
- IBRX Immunitybio Incindustry
- SRPT Sarepta Therapeutics Incindustry
- CRSP Crispr Therapeutics AGindustry
- TGTX TG Therapeutics Incindustry
- EXEL Exelixis Incindustry
- INCY Incyte Corporationindustry
- MRVI Maravai Lifesciences Holdings Incindustry